Jeil Pharma Holdings Inc. (002620)
KRX SM KRX SM Primary Summary
Jeil Pharma Holdings Inc. (002620) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Jeil Pharma Holdings Inc. ever had a stock split?
Jeil Pharma Holdings Inc. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Mr. Seung-Soo Han CEO | KRX SM Exchange | KR7002620003 ISIN |
| KR Country | 37 Employees | 29 Dec 2025 Last Dividend | 19 Apr 2006 Last Split | - IPO Date |
Overview
Jeil Pharma Holdings Inc is a prominent entity based in Seoul, South Korea, that holds specialization in the pharmaceutical sector. Founded in 1959, the company has carved a niche in manufacturing and marketing a vast array of pharmaceutical ingredients and drugs, catering to both the domestic and international markets. The company distinguishes itself by offering a broad spectrum of products, including active pharmaceutical ingredients (APIs), incrementally modified drugs, and generic drugs, across a multitude of therapeutic areas. With a strong export network, Jeil Pharma Holdings Inc extends its reach to around 40 countries across diverse regions like the Association of Southeast Asian Nations (ASEAN), Central and South America, and Africa, demonstrating its global footprint and commitment to addressing health needs worldwide.
Products and Services
Jeil Pharma Holdings Inc’s product portfolio is extensive and diversified, encapsulating a wide range of therapeutic categories:
- Active Pharmaceutical Ingredients (APIs): These are the essential components used in the formulation of drugs. Jeil Pharma Holdings Inc produces APIs across various therapeutic areas, including antibiotics, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamines, along with offering innovative patch products.
- Finished Dosage Forms: The company also specializes in the manufacturing of finished dosage forms. This encompasses an array of drugs targeted towards anti-bacteria and anti-fungal, anti-virus, cardiovascular, endocrinology, neurology, gastrointestinal, urology, oncology, anti-histamine, rheumatology, respiratory, otolaryngological, hepatic, and the provision of laxatives and purgatives.
- Global Outreach: Further augmenting its market presence, Jeil Pharma Holdings Inc exports its products globally. The company has established a significant export footprint in approximately 40 countries across strategic regions such as ASEAN, Central and South America, and Africa. This global distribution underscores its role as a key player in the international pharmaceutical marketplace.
